Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
Jad Othman, Charlotte S. Wilhelm-Benartzi, Richard Dillon, et al.
Blood Advances (2023) Vol. 7, Iss. 16, pp. 4539-4549
Open Access | Times Cited: 20

Showing 20 citing articles:

Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management
Shai Shimony, Maximilian Stahl, Richard M. Stone
American Journal of Hematology (2025)
Open Access | Times Cited: 3
Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors
Eleonora Boscaro, Irene Urbino, Federica Maria Catania, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3512-3512
Open Access | Times Cited: 16
Risk Stratification in Older Intensively Treated Patients With AML
Jurjen Versluis, Marlen Metzner, Ariel Wang, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 34, pp. 4084-4094
Closed Access | Times Cited: 6
Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances
Nishanth Thalambedu, Bhavesh Mohan Lal, Brent K. Harbaugh, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 508-508
Open Access
TP53‐Mutated Acute Myeloid Leukemia: Review of Treatment and Challenges
Bipin Ghimire, Markie Zimmer, Vijayalakshmi Donthireddy
European Journal Of Haematology (2025)
Open Access
Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia – long-term follow-up with focus on younger patients
Christina Rautenberg, Jan Moritz Middeke, Christoph Röllig, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
A Real-World Evaluation of Frontline Treatment for Acute Myeloid Leukemia with Azacitidine plus Venetoclax
Joseph Brandwein, David Page, Elena Liew, et al.
Clinical Lymphoma Myeloma & Leukemia (2025)
Open Access
Novel insights and therapeutic approaches in secondary AML
Giovanni Marconi, Michela Rondoni, Beatrice Anna Zannetti, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
Allogeneic Stem Cell Transplantation in Refractory Acute Myeloid Leukaemia
Roberto Bono, Giuseppe Sapienza, Stefania Tringali, et al.
Cells (2024) Vol. 13, Iss. 9, pp. 755-755
Open Access | Times Cited: 2
Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemia
Francesca Kinsella, Maria A. L. Maroto, Justin Loke, et al.
British Journal of Haematology (2024) Vol. 204, Iss. 6, pp. 2173-2183
Open Access | Times Cited: 1
Updates in biology, classification, and management of acute myeloid leukemia with antecedent hematologic disorder and therapy related acute myeloid leukemia
Kanak Parmar, Rupayan Kundu, Abhishek Maiti, et al.
Leukemia Research (2024) Vol. 144, pp. 107546-107546
Closed Access | Times Cited: 1
CREST‐UK: Real‐world effectiveness, safety and outpatient delivery of CPX‐351 for first‐line treatment of newly diagnosed therapy‐related AML and AML with myelodysplasia‐related changes in the UK
Priyanka Mehta, Victoria Campbell, Jamie Maddox, et al.
British Journal of Haematology (2024)
Open Access | Times Cited: 1
Nontransplant treatment approaches for myeloid neoplasm with mutated TP53
Ansh Mehta, Marina Konopleva
Hematology (2024) Vol. 2024, Iss. 1, pp. 326-334
Closed Access | Times Cited: 1
Practical considerations in clinical application of WHO 5th and ICC classification schemes for acute myeloid leukemia
Daniel J. Chandra, Curtis A. Lachowiez, Sanam Loghavi
Blood Reviews (2023) Vol. 64, pp. 101156-101156
Closed Access | Times Cited: 3
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes
Michael J. Hochman, Amy E. DeZern
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 9, pp. 573-582
Closed Access
FLAG/FLAG-Ida Regimen in Secondary and Relapsed/Refractory Acute Myeloid Leukemia—Even in the Era of New Treatment Modalities Still a Significant Player
Saša Anžej Doma, Matjaž Sever, Gorazd Jakoš, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 7, pp. 1842-1842
Open Access
Transplant Eligible and Ineligible Elderly Patients with AML—A Genomic Approach and Next Generation Questions
Paul Sackstein, Alexis K. Williams, Rachel Zemel, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 975-975
Open Access
Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data
Christoph Abé, Jaana Keto, Mathias Lilja, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024), pp. 1-9
Open Access
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient
Michael Heuser, Rabia Shahswar
Hematology (2024) Vol. 2024, Iss. 1, pp. 158-167
Closed Access
Comparing Outcomes Between CPX‐351 and Fludarabine‐Based Induction in Secondary Acute Myeloid Leukemia in the Real‐World Setting: The Prognostic Role of Measurable Residual Disease
Carola Riva, Paola Minetto, Maria Chies, et al.
Hematological Oncology (2024) Vol. 43, Iss. 1
Closed Access
Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML – A systematic review
Adi Sherban, David Fredman, Shai Shimony, et al.
Leukemia Research (2023) Vol. 133, pp. 107368-107368
Closed Access | Times Cited: 1
Page 1

Scroll to top